Trial Profile
Observer-blind Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2186877A in Elderly Subjects.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 07 Dec 2011 Actual end date changed from Nov 2009 to Dec 2009 as reported by ClinicalTrials.gov.
- 18 Dec 2009 Actual number of patients (192) added as reported by Clinicaltrials.gov record.
- 18 Dec 2009 Actual end date (1 Nov 2009) added as reported by Clinicaltrials.gov record.